Rutin

Pharmacology & Research

Rutin is quercetin carrying the disaccharide rutinose at its 3-O position — and two facts govern everything written about it. First, it is a poorly-absorbed prodrug of quercetin: the intact molecule mostly survives the small intestine and is cleaved by colonic bacteria to quercetin, so what reaches the blood is quercetin metabolites, hours later and highly variable between people ^{15,16,17Reference 15Hollman PC et al. · 1995Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteersView study →Reference 16Hollman PC et al. · 1997Relative bioavailability of the antioxidant flavonoid quercetin from various foods in manView study →Reference 17Erlund I et al. · 2000Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteersView study →}. Second, and consequently, most of rutin’s clinical reputation actually belongs to semi-synthetic derivatives — the hydroxyethylrutosides (oxerutins, Venoruton) and troxerutin, engineered for solubility precisely because plain rutin absorbs so poorly. Read “rutin has strong venous evidence” with both caveats in front of it: the venous trials are of the derivatives, not the raw compound.

1. Chronic venous insufficiency

The main clinical area — and the clearest illustration of the derivative caveat. The anchor is the Cochrane review of phlebotonics (2020), which found moderate-certainty evidence that the phlebotonic class reduces oedema versus placebo (rutosides being the largest subgroup), with low-certainty or no benefit for ulcer healing and only modest overall clinical relevance ^{1Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →}. A dedicated systematic review of hydroxyethylrutosides (15 RCTs, 1,643 patients) found significant reductions in pain, cramps and leg heaviness while judging the base “inconclusive” on hard efficacy ^{2Reference 2Aziz Z et al. · 2015Systematic reviewA systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiencyView study →}; representative placebo-controlled trials of oxerutins improved venous tone, microcirculation and oedema ^{3,4Reference 3Petruzzellis V et al. · 2002RCTOxerutins (Venoruton) — efficacy in chronic venous insufficiency, a double-blind, randomised, controlled studyView study →Reference 4Cesarone MR et al. · 2002RCTTreatment of oedema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton) — placebo-controlled, randomised, dose-ranging trialView study →}, with long-term tolerability supported over 5 years ^{5Reference 5Stuard S et al. · 2008Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides — safety aspectsView study →}, and a coumarin/troxerutin-combination trial confirmed an oedema-protective effect on stopping compression ^{8Reference 8Vanscheidt W et al. · 2002RCTThe efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency — a double-blind placebo-controlled randomised studyView study →}.

Gap: the evidence is for engineered derivatives (oxerutins/HR) at gram-level doses, mostly older, industry-associated, small-to-moderate trials using surrogate endpoints (plethysmography, capillaroscopy) rather than patient-important outcomes. For plain rutin there are essentially no modern monotherapy RCTs — so the honest score for rutin itself is closer to 25–30% ^{1,2Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →Reference 2Aziz Z et al. · 2015Systematic reviewA systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiencyView study →}.

2. Haemorrhoidal disease

A double-blind multicentre RCT of a flavonoid mixture (diosmin + troxerutin + rutin + hesperidin + quercetin) reduced bleeding and symptoms in grade I–III haemorrhoids ^{6Reference 6Corsale I et al. · 2018RCTFlavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I–III degree haemorrhoidal disease — a double-blind multicentre prospective comparative studyView study →}, and a placebo-controlled trial of parenteral troxerutin + carbazochrome improved post-haemorrhoidectomy recovery ^{7Reference 7Basile M et al. · 2001RCTParenteral troxerutin and carbazochrome combination in the treatment of post-haemorrhoidectomy status — a randomised, double-blind, placebo-controlled, phase IV studyView study →}.

Gap: rutin appears only as one ingredient in multi-flavonoid blends (or as the troxerutin derivative), so its independent contribution cannot be isolated. The evidence is for combination products, not rutin monotherapy ^{6,7Reference 6Corsale I et al. · 2018RCTFlavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I–III degree haemorrhoidal disease — a double-blind multicentre prospective comparative studyView study →Reference 7Basile M et al. · 2001RCTParenteral troxerutin and carbazochrome combination in the treatment of post-haemorrhoidectomy status — a randomised, double-blind, placebo-controlled, phase IV studyView study →}.

3. Antiplatelet & antithrombotic (PDI)

Rutin’s most scientifically distinctive finding. A landmark study identified rutin as an inhibitor of extracellular protein disulfide isomerase (PDI) — an enzyme released by activated platelets and endothelium that is required for thrombus formation — and showed rutin blocked thrombosis in vivo, upstream of both platelet aggregation and fibrin generation ^{9Reference 9Jasuja R et al. · 2012Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents (rutin as prototype)View study →}. This is a genuinely rutin-specific mechanism.

Gap: the human program switched to the better-absorbed sibling isoquercetin (quercetin-3-glucoside): proof-of-mechanism in people ^{10Reference 10Stopa JD et al. · 2017Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activationView study →} and a phase-II cancer trial (1,000 mg/day) that inhibited plasma PDI and lowered D-dimer with no VTE or major bleeds ^{11Reference 11Zwicker JI et al. · 2019Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerView study →}. A rutin nano-formulation was later needed to restore the effect in animals — tacitly conceding that plain oral rutin is too poorly absorbed to deliver it ^{12Reference 12Chen D et al. · 2022Orally delivered rutin in a lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibitionView study →}. Score it high on mechanism, low on plain-rutin human proof ^{9,12Reference 9Jasuja R et al. · 2012Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents (rutin as prototype)View study →Reference 12Chen D et al. · 2022Orally delivered rutin in a lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibitionView study →}.

4. Capillary fragility (“vitamin P”)

The oldest claim, and a cautionary tale. In the 1930s rutin and citrus flavonoids were proposed as “vitamin P” (P for permeability) for capillary fragility — a designation later withdrawn because flavonoids are not vitamins and the early clinical work was uncontrolled ^{1Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →}. Modern oxerutin trials do show improvements in capillary filtration and a plasma antioxidant signal on surrogate endpoints ^{13Reference 13Cesarone MR et al. · 2002RCTVariations in plasma free radicals in venous hypertension with HR (Paroven, Venoruton) — placebo-controlled, randomised trialView study →}, and a 1940s rutin series in diabetic retinopathy is of historical interest only ^{14Reference 14Levitt LM · 1948Rutin therapy for increased capillary fragility and retinopathy associated with diabetes mellitusView study →}.

Gap: no rigorous modern trial shows plain rutin meaningfully improves clinical capillary-fragility outcomes; only the mechanistic microcirculation kernel survives, on surrogate measures ^{1,13Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →Reference 13Cesarone MR et al. · 2002RCTVariations in plasma free radicals in venous hypertension with HR (Paroven, Venoruton) — placebo-controlled, randomised trialView study →}.

Mechanisms

Target / pathway	Effect	Carried by	Relevant to
Venotonic / capillary-sealing	↑ venous wall tone, ↓ capillary filtration & oedema	chiefly oxerutins/HR & troxerutin (derivatives); plain rutin weakly	venous insufficiency, haemorrhoids
Antioxidant / radical scavenging	↓ oxidative stress in venous hypertension	rutin & derivatives	microcirculation, capillary fragility
PDI (protein disulfide isomerase) inhibition	blocks platelet-dependent thrombin generation & thrombosis, upstream of aggregation	rutin specifically (isoquercetin in humans)	antithrombotic
Prodrug → quercetin (colonic cleavage)	bacteria remove rutinose → quercetin absorbed; systemic effects are quercetin’s	rutin as delivery vehicle	any systemic antioxidant/anti-inflammatory claim

Pharmacokinetics

Rutin is best understood as a poorly-absorbed colonic prodrug of quercetin. The rhamnose-glucose cap (rutinose) resists the small intestine’s β-glucosidases — which can free quercetin glucosides for early absorption — so rutin must reach the colon, where microbiota strip the sugars and release quercetin for uptake ^{15,16Reference 15Hollman PC et al. · 1995Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteersView study →Reference 16Hollman PC et al. · 1997Relative bioavailability of the antioxidant flavonoid quercetin from various foods in manView study →}. In ileostomy volunteers, quercetin glucosides from onions were ~52% absorbed but the rutinoside only ~17% ^{15Reference 15Hollman PC et al. · 1995Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteersView study →}; in intact people, rutin delivered only ~30% of the relative bioavailability of onion glucosides, and plasma quercetin peaked at ~9 h (versus <1 h for onions) — the signature of colonic handling ^{16,17Reference 16Hollman PC et al. · 1997Relative bioavailability of the antioxidant flavonoid quercetin from various foods in manView study →Reference 17Erlund I et al. · 2000Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteersView study →}. Because that cleavage is done by gut bacteria, absorption is microbiome-dependent and highly variable between individuals ^{18Reference 18Riva A et al. · 2020Conversion of rutin, a prevalent dietary flavonol, by the human gut microbiotaView study →}.

Three consequences: the circulating species is quercetin conjugates, not intact rutin; inter-individual variability is large; and this is exactly why the semi-synthetic hydroxyethylrutosides / troxerutin were engineered — hydroxyethylating rutin’s phenols yields a more soluble, better-standardised derivative for venoactive medicine, a distinct entity from dietary rutin ^{19Reference 19Bianchi M et al. · 2018Troxerutin, a mixture of O-hydroxyethyl derivatives of the natural flavonoid rutin — chemical stability and analytical aspectsView study →}.

Clinical trials

Rutin’s trial record is substantial but sits mostly under its derivatives: dozens of oxerutin/hydroxyethylrutoside and troxerutin trials in venous disease (pooled by Cochrane), plus combination-product haemorrhoid trials. Trials of plain rutin monotherapy are scarce and mostly old; the modern antithrombotic program moved to isoquercetin.

Venous (derivatives)	Haemorrhoids (combos)	Antithrombotic	Plain-rutin monotherapy
Many RCTs + Cochrane	Several RCTs	Human (isoquercetin)	Very few / historical

Last checked: July 2026.

Isolate vs. Plant Studies

Rutin is unusually easy to over-credit, in three directions. The clinical evidence is mostly for a different molecule: the venous-disease data belong to the semi-synthetic oxerutins/hydroxyethylrutosides and troxerutin, and the antithrombotic human data to isoquercetin — plain rutin is the raw material, not the tested agent ^{1,11,19Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →Reference 11Zwicker JI et al. · 2019Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerView study →Reference 19Bianchi M et al. · 2018Troxerutin, a mixture of O-hydroxyethyl derivatives of the natural flavonoid rutin — chemical stability and analytical aspectsView study →}. The systemic pharmacology is mostly quercetin’s: because rutin is cleaved to quercetin before absorption, its antioxidant/anti-inflammatory “effects” are largely quercetin-metabolite effects ^{16Reference 16Hollman PC et al. · 1997Relative bioavailability of the antioxidant flavonoid quercetin from various foods in manView study →}. And in herbs, rutin is a co-occurring flavonoid, repeatedly named alongside quercetin in the antioxidant fraction of plants like hawthorn, calendula, buchu, hibiscus and goldenrod — usually as a whole-extract contributor, and often with its actions bundled with quercetin’s rather than demonstrated for rutin alone. Note too that horse-chestnut’s venous reputation belongs to escin, not to the rutin it also contains. Read the venous evidence as evidence for oxerutins, the antithrombosis as evidence for the mechanism (and for isoquercetin), and rutin itself as a food-derived quercetin delivery form.

Prevalence in Nature

Rutin is one of the most widely distributed flavonol glycosides in the plant kingdom — quercetin bearing rutinose (rhamnose-α(1→6)-glucose) at the 3-O position — occurring across many families but reaching its highest food concentrations in buckwheat (Fagopyrum) ^{23,24Reference 23Ganeshpurkar A · 2017The pharmacological potential of rutin (occurrence, biosynthesis, food contents)View study →Reference 24Habtemariam S · 2019Antioxidant and rutin content analysis of leaves of the common buckwheat (Fagopyrum esculentum Moench) grown in the United KingdomView study →}. Within buckwheat there is a large split: Tartary buckwheat (F. tataricum) carries roughly 5–10× more rutin than common buckwheat, and the green vegetative tissue dwarfs the grain — common-buckwheat leaves run ~2–3 g/100 g on a dry-weight basis (with the wider literature citing 2–10 g/100 g DW), which is why buckwheat sprouts, leaves and Tartary flour/bran are the standout dietary sources ^{24,25Reference 24Habtemariam S · 2019Antioxidant and rutin content analysis of leaves of the common buckwheat (Fagopyrum esculentum Moench) grown in the United KingdomView study →Reference 25Suzuki T et al. · 2015Rutin, quercetin, and free amino acid analysis in buckwheat (Fagopyrum) seeds from different locationsView study →}. Thermal/wet processing degrades it (endogenous rutinosidase converts rutin to quercetin). Beyond buckwheat, notable sources include capers (~332 mg/100 g), black olives, asparagus, citrus and peels, elderberry/elderflower, rue, unripe figs and apple peel ^{23,26Reference 23Ganeshpurkar A · 2017The pharmacological potential of rutin (occurrence, biosynthesis, food contents)View study →Reference 26Lee J · 2016Variation of select flavonols and chlorogenic acid content of elderberry collected throughout the eastern United States (rutin the principal flavonol)View study →}. The pharmaceutical raw material, however, is usually the exceptionally rich flower buds of the Japanese pagoda tree (Sophora japonica, up to ~15–20% rutin), not a food ^{23Reference 23Ganeshpurkar A · 2017The pharmacological potential of rutin (occurrence, biosynthesis, food contents)View study →}.

Biosynthetically, rutin is quercetin (built through the phenylpropanoid → flavonoid pathway) finished by two glycosylation steps: a 3-O-glucosyltransferase adds glucose to give isoquercitrin, then a rhamnosyltransferase adds rhamnose (1→6) to complete the rutinoside ^{23Reference 23Ganeshpurkar A · 2017The pharmacological potential of rutin (occurrence, biosynthesis, food contents)View study →}. Accumulation is strongly induced by UV-B and abiotic stress, consistent with a photoprotective/antioxidant role. There is essentially no non-plant source.

Discovery & Synthesis

“Rutin” is taken directly from Ruta graveolens (common rue), the plant from which it was obtained and named in the nineteenth century (commonly dated to ~1842 and attributed to the chemist August Weiss — a detail I could confirm only through secondary sources, so treat the date and author as reported-but-unverified). It has also been called rutoside, sophorin, and by its systematic name quercetin-3-O-rutinoside. In the 1930s rutin became central to the “vitamin P” episode: Szent-Györgyi and colleagues proposed a “vitamin P” (for permeability) to explain citrus-flavonoid effects on capillary fragility — a designation later discredited, since flavonoids are not vitamins, though the vascular framing is why rutin’s derivatives persist in venoactive medicine.

Structurally, rutin is the flavonol quercetin bearing rutinose (rhamnose-(1→6)-glucose) at the 3-O position — the specific rhamnosyl cap that defies small-intestinal enzymes and forces colonic activation. Commercially it is extracted from plants, not synthesised: the dominant feedstocks are Sophora japonica flower buds (~15–20% rutin) and, especially in Brazil, Dimorphandra mollis (fava d’anta), with buckwheat a lower-yield source ^{22Reference 22Paniwnyk L et al. · 2001The extraction of rutin from flower buds of Sophora japonicaView study →}. These same rutin-rich feedstocks are the starting material for commercial quercetin (made by hydrolysing the rutinose off rutin) and for the hydroxyethylrutosides/troxerutin (made by hydroxyethylating rutin) — so rutin, quercetin and the oxerutins are three products of one supply chain ^{19,22Reference 19Bianchi M et al. · 2018Troxerutin, a mixture of O-hydroxyethyl derivatives of the natural flavonoid rutin — chemical stability and analytical aspectsView study →Reference 22Paniwnyk L et al. · 2001The extraction of rutin from flower buds of Sophora japonicaView study →}.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Rutin has an exceptionally benign safety profile and a long history of dietary and supplemental exposure (buckwheat, apples, tea, citrus). In genotoxicity testing it behaves as expected for a food flavonol — no bone-marrow micronucleus induction in mice, and DNA damage only at extreme oral doses — so ordinary consumption is not considered clastogenic ^{21Reference 21da Silva J et al. · 2002Evaluation of the genotoxic effect of rutin and quercetin by comet assay and micronucleus testView study →}, and its poor intact absorption further limits systemic exposure. The “vitamin P” label is a historical misnomer, not a nutritional classification.

The interaction signals it carries are inherited from quercetin, because rutin is functionally a quercetin prodrug. In a controlled animal study, rutin markedly reduced the oral bioavailability of the immunosuppressant cyclosporine (AUC down ~57%) via P-glycoprotein and CYP3A4 — a meaningful caution for that narrow-margin drug and, by extension, other CYP3A/P-gp substrates ^{20Reference 20Yu CP et al. · 2011Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral through activating P-glycoprotein and CYP 3A4View study →}. And because rutin/quercetin have antiplatelet and PDI-inhibiting activity, caution is reasonable alongside anticoagulant or antiplatelet drugs (warfarin, clopidogrel, aspirin) on additive-bleeding grounds — a precautionary, mechanism-based flag rather than a documented bleeding series ^{9,20Reference 9Jasuja R et al. · 2012Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents (rutin as prototype)View study →Reference 20Yu CP et al. · 2011Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral through activating P-glycoprotein and CYP 3A4View study →}.

Dosage

There is no established dose of plain rutin, because its own clinical trials are scarce — the venous-disease evidence used the semi-synthetic oxerutins / hydroxyethylrutosides at roughly 0.9–1 g/day ^{1,2,3Reference 1Martinez-Zapata MJ et al. · 2020Systematic reviewPhlebotonics for venous insufficiencyView study →Reference 2Aziz Z et al. · 2015Systematic reviewA systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiencyView study →Reference 3Petruzzellis V et al. · 2002RCTOxerutins (Venoruton) — efficacy in chronic venous insufficiency, a double-blind, randomised, controlled studyView study →}, and the antithrombotic human evidence used isoquercetin (500–1,000 mg/day), not rutin ^{11Reference 11Zwicker JI et al. · 2019Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerView study →}. Dietary rutin intake from buckwheat, capers and citrus is far lower and is not standardised.

These are doses used in research on the derivatives, not a recommendation for plain rutin — whose poor, microbiome-dependent absorption means an oral dose delivers mostly quercetin metabolites, variably. Anyone on anticoagulants or narrow-margin drugs (see interactions) should seek professional guidance.

References